

Q4 2022: What's new in Selector (Reagents and model systems)


Last Modified on 12/04/2023 12:28 am EDT

We are excited to announce new enhancements on the platform between October and December 2022

Over the past three months, we've added data from over **6.3 million experiments** and **367,000 products** across all reagent and model system types. Other notable updates include:

1. Improved visibility of Cas nuclease usage from publication-derived data

In addition to viewing data for commercially available Cas nuclease products, we've improved our technology to detect Cas nuclease usage from the literature. Applying the *Cas Type* filter now reveals results for both commercially available Cas nuclease products and results for custom in-house generated Cas nucleases.



Company	Search Cas Type	Published Figures	Supplier Figures
Cas Nuclease Specs	<input type="checkbox"/> Cas9	30.1K	4
Cas Nuclease Format	<input type="checkbox"/> Cas9 null	4.2K	0
Cas Type	<input type="checkbox"/> Cas9 nickase	1.5K	1
Modification	<input type="checkbox"/> Cas13	1K	0
Purity	<input type="checkbox"/> Cas12a	966	0
Purification Method	<input type="checkbox"/> Sacas9	477	1
Formulation	<input type="checkbox"/> Cas13 null	246	0
Vector Format			

2. More data for xenograft, patient-derived xenograft, and allograft animal models

Grafting models are often used in oncology research to introduce a donor tissue or cell line into a mouse model, to study downstream disease phenotypes. We surface literature-mined grafting models through a specific set of **application** names: xenograft, patient-derived xenograft, and allograft. We recently improved our algorithms to detect more data from the literature for these applications to empower scientists with more information as they are reviewing which animal models to use.

Patient-Derived Xenograft


Animal Model - Mouse

XEN PDX

Athymic Nude-Foxn1^{nu} model was used in this figure

No Catalog # was cited

See All Athymic Nude-Foxn1^{nu} Mouse Models >



Please note that access to these features and enhancements will depend on which reagents and model systems are available at your organization.